1,721,091 research outputs found
Antihypertensive drugs and risk of skin cancer
No full textThe potential carcinogenic risk of antihypertensive drugs has been examined in several studies that reported controversial results. The association between treatment with antihypertensives and risk of skin cancer has also been questioned, considering the longterm administration of such drugs and the ability of some agents to cause photosensitive reactions. In fact, experimental and epidemiologic findings suggest a link between druginduced photosensitivity and skin cancer, possibly through the induction of DNA damage in predisposed individuals. Antihypertensive medications might influence skin homeostasis through additional mechanisms. For instance, some antihypertensive drugs can affect epidermal differentiation by interfering with calcium or sodium channels in the skin. Mediators in the reninangiotensin system (RAS) are also involved in the modulation of cellular proliferation and angiogenesis. Of note, the existence of RAS has been recognized in many organs and tissues, including the skin. The available data regarding the relationship between use of different types of antihypertensives and skin cancer risk do not allow to draw definite conclusions at present. The aim of this article is to summarize the current evidence about the association of antihypertensive use with risk of nonmelanoma skin cancer, melanoma, lip cancer and cutaneous lymphoma. A brief mention of the role of betablockers in melanoma progression has also been added
Photodynamic therapy for the treatment of micro invasive squamous cell carcinoma of the lower lip: a case report
No full textPhotodynamic therapy (PDT) with methyl aminolevulinate (MAL) is approved in Europe for the treatment of actinic keratosis and Bowen's disease, both intraepithelial forms of squamous cell carcinoma (SCC). A therapeutic effect of MAL--PDT has been recently suggested for superficial, microinvasive and well--differentiated cutaneous SCC. We describe the successful use of MAL--PDT in a recently observed patient with microinvasive SCC of the lower lip and review published data on the use of PDT with MAL or --aminolevulinic acid (ALA) in cutaneous microinvasive SCC. A patient with a biopsy--proven recurrent microinvasive SCC of the lower lip was treated with 2 cycles of MAL--PDT. Complete clinical, dermoscopic and histopathological clearance was obtained after 2 cycles of MAL--PDT with an excellent cosmetic result and a sustained remission after 24--month follow--up. A review of the few studies reporting on the use of MAL--PDT or ALA--PDT for cutaneous microinvasive SCCs was carried out. MAL--PDT might represent a non--invasive treatment option for microinvasive SCC of the lower lip if patients are not eligible for surgery. Post--treatment histopathological confirmation and a long--term follow--up are strictly recommended
Practical indications for the management of non-melanoma skin cancer patients
No full textBasal cell carcinoma (BCC) and squamous cell carcinoma (SCC), together encompassed in the term non-melanoma skin cancers (NMSC), are the most common cancers among fair-skinned populations. Individuating accurate risk stratification of NMSC patients is crucial to select different options among various treatment strategies. The majority of low risk NM SCs are easily treated with surgery, offering excellent cure rates and cosmetic results. Other treatment modalities include physical destruction (curettage, cautery and cryotherapy), chemical destruction (photodynamic therapy and topical 5-flurouracil) and immunomodulatory therapy (topical imiquimod). However, there is a subset of "high-risk" NM SC characterized by prognostic factors associated to aggressive behavior, such as tumor location and size, clinical margins, histopathological variants, recurrence or previous treatment. These lesions need to be treated accordingly also by mean of adjuvant treatments. The contribution of a multidisciplinary team is necessary to appropriately manage patients affected by advanced NM SC. The aim of these practical indications is to provide a useful guidance for risk stratification of NMSC patients in clinical setting and for consequential treatment choice, resulting in individualized management strategies
Lentigo maligna: diagnosis and treatment
No full textLentigo maligna (LM) is an in situ subtype of melanoma, clinically presenting as a pigmented, asymmetric macule that originates mostly on the head and neck and spreads slowly. The diagnosis may be challenging both for clinicians and pathologists. Dermatoscopy and reflectance confocal microscopy represent a useful tool in the differentiation of LM from other pigmented lesions, such as pigmented actinic keratosis, solar lentigines, seborrheic keratosis and lichen planus-like keratosis. Moreover, those non-invasive diagnostic technique may be crucial in the selection of optimal biopsy sites in equivocal lesions, in pre-surgical mapping and in evaluating and monitoring response to non-surgical treatments. Histologic examination remains the gold standard for the diagnosis of LM, showing a lentiginous proliferation of basal atypical melanocytes on a severe sun- damaged skin. The management of LM is constantly evolving. Treatments include surgery (the first choice, when available), radiotherapy and imiquimod cream (in patients not candidates to surgery). Many other possible treatments for LM have been tested, but they are not yet supported by strong evidences. We collected current guidelines and PubMed available reviews, studies and case-reports in order to make an overview on diagnosis and treatment of LM
Use of reflectance confocal microscopy to diagnose occult basal cell carcinoma: 2 case reports
No full textnon
Digital imaging of ink spot lentigo: Confocal microscopy and line‐field confocal optical coherence tomography assessment
No full textNo Abstrac
- …
